Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top

Small Cell Lung Cancer—An Update on Chemotherapy Resistance

or
Journals by subject

Editor's Choice | Journals

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest Journal Issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Stay up to date with medical journals in your specialty

Already registered? Log in here

Register today

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

Latest issues in Internal Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Cardiology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Diabetes & Endocrinology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Neurology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Oncology

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Pediatrics

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Latest issues in Respiratory Medicine

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer. 

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe. 

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area. 

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.
Current Treatment Options in Oncology
Published in:

27-07-2024 | SCLC

Small Cell Lung Cancer—An Update on Chemotherapy Resistance

Authors: Qian Ying, Ruiyun Fan, Yili Shen, Boyi Chen, Jianhui Zhang, Qiuhui Li, Xuefei Shi

Published in: Current Treatment Options in Oncology | Issue 8/2024

Login to get access

Opinion Statement

Compared to other types of lung cancer, small cell lung cancer (SCLC) exhibits aggressive characteristics that promote drug resistance. Despite platinum-etoposide chemotherapy combined with immunotherapy being the current standard treatment, the rapid development of drug resistance has led to unsatisfactory clinical outcomes. This review focuses on the mechanisms contributing to the chemotherapy resistance phenotype in SCLC, such as increased intra-tumoral heterogeneity, alterations in the tumor microenvironment, changes in cellular metabolism, and dysregulation of apoptotic pathways. A comprehensive understanding of these drug resistance mechanisms in SCLC is imperative for ushering in a new era in cancer research, which will promise revolutionary advancements in cancer diagnosis and treatment methodologies.
Literature
1.
Rodriguez E, Lilenbaum RC. Small cell lung cancer: past, present, and future. Curr Oncol Rep. 2010;12(5):327–34.PubMedCrossRef
2.
3.
Rudin CM, Poirier JT. Small-cell lung cancer in 2016: Shining light on novel targets and therapies. Nat Rev Clin Oncol. 2017;14(2):75–6.PubMedCrossRef
4.
5.
6.
Wang Q, Gumus ZH, Colarossi C, et al. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thorac Oncol. 2023;18(1):31–46.PubMedCrossRef
7.
Niu X, Chen L, Li Y, Hu Z, He F. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC. Semin Cancer Biol. 2022;86(Pt 3):273–85.PubMedCrossRef
8.
Petty WJ, Paz-Ares L. Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review. JAMA Oncol. 2023;9(3):419–29.PubMedCrossRef
9.
Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220–9.PubMedCrossRef
10.
Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol: off j Am Soc Clin Oncol. 2021;39(6):619–30.CrossRef
11.
Schenk MW, Humphrey S, Hossain A, et al. Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nat Commun. 2021;12(1):6652.PubMedPubMedCentralCrossRef
12.
Stewart CA, Gay CM, Xi Y, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1:423–36.PubMedPubMedCentralCrossRef
13.
Thirusangu P, Ray U, Sarkar Bhattacharya S, et al. PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma. Oncogene. 2022;41(33):4003–17.PubMedPubMedCentralCrossRef
14.
Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.PubMedCrossRef
15.
Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013;85(9):1219–26.PubMedCrossRef
16.
Dexter DL, Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol: off J Am Soc Clin Oncol. 1986;4(2):244–57.CrossRef
17.
Dentro SC, Leshchiner I, Haase K, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. 2021;1848:2239-54.e39.CrossRef
18.
Stanzione M, Zhong J, Wong E, et al. Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer. Sci Adv. 2022;8(19):eabn1229
19.
Lim JS, Ibaseta A, Fischer MM, et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature. 2017;545(7654):360–4.PubMedPubMedCentralCrossRef
20.
Falco JP, Baylin SB, Lupu R, et al. v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. J Clin Invest. 1990;85(6):1740–5.PubMedPubMedCentralCrossRef
21.
Mabry M, Nakagawa T, Nelkin BD, et al. v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer. Proc Natl Acad Sci USA. 1988;85(17):6523–7.PubMedPubMedCentralCrossRef
22.
Calbo J, van Montfort E, Proost N, et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell. 2011;19(2):244–56.PubMedCrossRef
23.
Wu Q, Guo J, Liu Y, et al. YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci Adv. 2021;7(40): eabg1850
24.
Galli GG, Carrara M, Yuan WC, et al. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. Mol Cell. 2015;60(2):328–37.PubMedPubMedCentralCrossRef
25.
26.
de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374–403.PubMedCrossRef
27.
Cabanos HF, Hata AN. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers (Basel). 2021;13(11):2666.PubMedCrossRef
28.
Giraldo NA, Sanchez-Salas R, Peske JD, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45–53.PubMedCrossRef
29.
Chan JM, Quintanal-Villalonga A, Gao VR, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39(11):1479-96.e18.PubMedPubMedCentralCrossRef
30.
Liu R, Shi P, Wang Z, Yuan C, Cui H. Molecular Mechanisms of MYCN Dysregulation in Cancers. Front Oncol. 2020;10:625332.PubMedCrossRef
31.
Grunblatt E, Wu N, Zhang H, et al. MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. Genes Dev. 2020;34(17–18):1210–26.PubMedPubMedCentralCrossRef
32.
Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84(3):345–57.PubMedCrossRef
33.
Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022;15(1):34.PubMedPubMedCentralCrossRef
34.
35.
Anderson EM, Thomassian S, Gong J, Hendifar A, Osipov A. Advances in Pancreatic Ductal Adenocarcinoma Treatment. Cancers (Basel). 2021;13(21):5510.PubMedCrossRef
36.
Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 1999;5(6):662–8.PubMedCrossRef
37.
Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005;65(18):8423–32.PubMedCrossRef
38.
Terranova VP, Liotta LA, Russo RG, Martin GR. Role of laminin in the attachment and metastasis of murine tumor cells. Cancer Res. 1982;42(6):2265–9.PubMed
39.
Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci USA. 1990;87(17):6698–702.PubMedPubMedCentralCrossRef
40.
Codony-Servat J, Verlicchi A, Rosell R. Cancer stem cells in small cell lung cancer. Transl Lung Cancer Res. 2016;5(1):16–25.PubMedPubMedCentral
41.
Guo W, Qiao T, Li T. The role of stem cells in small-cell lung cancer: evidence from chemoresistance to immunotherapy. Semin Cancer Biol. 2022;87:160–9.PubMedCrossRef
42.
Phi LTH, Sari IN, Yang YG, et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018;2018:5416923.PubMedPubMedCentralCrossRef
43.
44.
45.
Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628–32.PubMedPubMedCentralCrossRef
46.
Parada LF, Dirks PB, Wechsler-Reya RJ. Brain Tumor Stem Cells Remain in Play. J Clin Oncol: off J Am Soc Clin Oncol. 2017;35(21):2428–31.CrossRef
47.
Sarvi S, Mackinnon AC, Avlonitis N, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74(5):1554–65.PubMedCrossRef
48.
Yu J, Wang S, Zhao W, et al. Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel alpha2delta1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. Clin Cancer Res. 2018;24(9):2148–58.PubMedCrossRef
49.
Kursunel MA, Taskiran EZ, Tavukcuoglu E, et al. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes. Cancer Immunol Immunother. 2022;71(2):445–59.PubMedCrossRef
50.
51.
Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.PubMedCrossRef
52.
53.
54.
Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65(2):613–21.PubMedCrossRef
55.
Wagner W, Ciszewski WM, Kania KD. L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation. Cell Commun Signal. 2015;13:36.PubMedPubMedCentralCrossRef
56.
Botzer LE, Maman S, Sagi-Assif O, et al. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br J Cancer. 2016;114(7):759–66.PubMedCrossRef
57.
58.
Guerra B, Recio C, Aranda-Tavio H, Guerra-Rodriguez M, Garcia-Castellano JM, Fernandez-Perez L. The Mevalonate Pathway, a Metabolic Target in Cancer Therapy. Front Oncol. 2021;11:626971.PubMedPubMedCentralCrossRef
59.
Guo C, Wan R, He Y, et al. Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nat Cancer. 2022;3(5):614–28.PubMedCrossRef
60.
Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10(8):513–25.PubMedCrossRef
61.
62.
Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006;2(3):e40.PubMedPubMedCentralCrossRef
63.
Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev. 2010;90(1):291–366.PubMedCrossRef
64.
Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell. 2001; 105(4): 511-9
65.
Preisig-Muller R, Schlichthorl G, Goerge T, et al. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen’s syndrome. Proc Natl Acad Sci USA. 2002;99(11):7774–9.PubMedPubMedCentralCrossRef
66.
Sansone V, Griggs RC, Meola G, et al. Andersen’s syndrome: a distinct periodic paralysis. Ann Neurol. 1997;42(3):305–12.PubMedCrossRef
67.
Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen’s syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994;35(3):326–30.PubMedCrossRef
68.
Liu H, Huang J, Peng J, et al. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Mol Cancer. 2015; 14:59
69.
Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer. 2010;46(9):1692–702.PubMedCrossRef
70.
71.
Lam HD, Lemay AM, Kelly J, Hill CE. Loss of Kv and MaxiK currents associated with increased MRP1 expression in small cell lung carcinoma. J Cell Physiol. 2006;209(2):535–41.PubMedCrossRef
72.
Song Y, Sun Y, Lei Y, Yang K, Tang R. YAP1 promotes multidrug resistance of small cell lung cancer by CD74-related signaling pathways. Cancer Med. 2020;9(1):259–68.PubMedCrossRef
73.
Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature. 1996;384(6610):638–41.PubMedCrossRef
74.
Debatin KM, Beltinger C, Bohler T, et al. Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. Biochem Soc Trans. 1997;25(2):405–10.PubMedCrossRef
75.
Wu W, Wang HD, Guo W, et al. Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res. 2010;29(1):49.PubMedPubMedCentralCrossRef
76.
Luo M, Ye L, Chang R, et al. Multi-omics characterization of autophagy-related molecular features for therapeutic targeting of autophagy. Nat Commun. 2022;13(1):6345.PubMedPubMedCentralCrossRef
77.
78.
79.
80.
Xie K, Doles J, Hemann MT, Walker GC. Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci USA. 2010;107(48):20792–7.PubMedPubMedCentralCrossRef
81.
Coleman N, Zhang B, Byers LA, Yap TA. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer. 2021;124(5):857–9.PubMedCrossRef
82.
Zoppoli G, Regairaz M, Leo E, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci USA. 2012;109(37):15030–5.PubMedPubMedCentralCrossRef
83.
Gardner EE, Lok BH, Schneeberger VE, et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 2017;31(2):286–99.PubMedPubMedCentralCrossRef
84.
Scattolin D, Maso AD, Ferro A, et al. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer. Cancer Treat Rev. 2024;128:102768.PubMedCrossRef
85.
Krushkal J, Silvers T, Reinhold WC, et al. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. Clin Epigenetics. 2020;12(1):93.PubMedPubMedCentralCrossRef
86.
Brickner JR, Soll JM, Lombardi PM, et al. A ubiquitin-dependent signalling axis specific for ALKBH-mediated DNA dealkylation repair. Nature. 2017;551(7680):389–93.PubMedPubMedCentralCrossRef
87.
88.
Lukinovic V, Hausmann S, Roth GS, et al. SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. Cancer Discov. 2022;12(9):2158–79.PubMedPubMedCentralCrossRef
89.
Zhu B, Zhou X. The study of PI3K/AKT pathway in lung cancer metastasis and drug resistance. Zhongguo Fei Ai Za Zhi. 2011;14(8):689–94.PubMed
90.
Li X, Li C, Guo C, et al. PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer. J Genet Genomics. 2021;48(7):640–51.PubMedCrossRef
91.
Jin Y, Chen Y, Tang H, et al. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer. Clin Cancer Res. 2022;28(3):526–39.PubMedCrossRef
92.
Chen R, Li D, Zheng M, et al. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1. J Cell Mol Med. 2020;24(3):2123–34.PubMedPubMedCentralCrossRef
93.
Tripathi SC, Fahrmann JF, Celiktas M, et al. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. Cancer Res. 2017;77(16):4414–25.PubMedPubMedCentralCrossRef
94.
Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther. 2002;1(11):913–22.PubMed
95.
Moon H, Han KH, Ro SW. Pro-tumorigenic roles of TGF-beta signaling during the early stages of liver tumorigenesis through upregulation of Snail. BMB Rep. 2017;50(12):599–600.PubMedPubMedCentralCrossRef
96.
Lin A, Zhu L, Jiang A, Mou W, Zhang J, Luo P. Activation of the TGF-beta Pathway Enhances the Efficacy of Platinum-Based Chemotherapy in Small Cell Lung Cancer Patients. Dis Markers. 2022;2022:8766448.PubMedPubMedCentralCrossRef
97.
98.
Hayakawa A, Saitoh M, Miyazawa K. Dual Roles for Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) in Cancer Progression. Adv Exp Med Biol. 2017;925:33–40.PubMedCrossRef
99.
Zheng M, Niu Y, Bu J, et al. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-beta/Smad signaling. Aging (Albany NY). 2021;13(3):3554–72.PubMedCrossRef
100.
Huang W, Yang Y, Wu J, et al. Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-beta signalling. Cell Death Differ. 2020;27(5):1709–27.PubMedCrossRef
101.
Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br J Cancer. 2008;98(11):1803–9.PubMedPubMedCentralCrossRef
102.
Yao Z, Lin A, Yi Y, Shen W, Zhang J, Luo P. THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients. Drug Des Devel Ther. 2022;16:1679–95.PubMedPubMedCentralCrossRef
103.
Chen YX, Wang CJ, Xiao DS, et al. eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer. Pharmacol Res. 2021;174:105934.PubMedCrossRef
104.
He J, Zhu S, Liang X, et al. LncRNA as a multifunctional regulator in cancer multi-drug resistance. Mol Biol Rep. 2021;48(8):1–15.PubMedCrossRef
105.
Li D, Shen Y, Ren H, Wang L, Yang J, Wang Y. Repression of linc01555 up-regulates angiomotin-p130 via the microRNA-122-5p/clic1 axis to impact vasculogenic mimicry-mediated chemotherapy resistance in small cell lung cancer. Cell Cycle. 2023;22(2):255–68.PubMedCrossRef
106.
Wang X, Li X, Niu L, et al. FAK-LINC01089 negative regulatory loop controls chemoresistance and progression of small cell lung cancer. Oncogene. 2024;43(22):1669–87.PubMedCrossRef
107.
Zeng F, Wang Q, Wang S, et al. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene. 2020;39(2):293–307.PubMedCrossRef
108.
Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524–9.PubMedPubMedCentralCrossRef
109.
Ranade AR, Cherba D, Sridhar S, et al. MicroRNA 92a–2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol. 2010;5(8):1273–8.PubMedCrossRef
110.
Wang Z, Fu S, Zhao J, et al. Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. Cancer Lett. 2019;440–441:180–8.PubMedCrossRef
111.
Huang H, Weng H, Chen J. m(6)A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020;37(3):270–88.PubMedPubMedCentralCrossRef
112.
Zhang Z, Zhang C, Yang Z, et al. m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. J Hematol Oncol. 2021;14(1):190.PubMedPubMedCentralCrossRef
113.
Belgiovine C, Bello E, Liguori M, et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer. 2017;117(5):628–38.PubMedPubMedCentralCrossRef
114.
Santamaria Nunez G, Robles CM, Giraudon C, et al. Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells. Mol Cancer Ther. 2016;15(10):2399–412.PubMedCrossRef
115.
Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21(5):645–54.PubMedCrossRef
116.
Koinis F, Agelaki S, Karavassilis V, et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer. 2017;117(1):8–14.PubMedPubMedCentralCrossRef
117.
Ready N, Farago AF, de Braud F, et al. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14(2):237–44.PubMedCrossRef
118.
Ready NE, Ott PA, Hellmann MD, et al. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. J Thorac Oncol. 2020;15(3):426–35.PubMedCrossRef
119.
Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(☆). Ann Oncol. 2021;32(5):631–41.PubMedCrossRef
120.
Kim JW, Ko JH, Sage J. DLL3 regulates Notch signaling in small cell lung cancer iScience. 2022; 25(12): 105603
121.
Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet. 2011;20(5):905–16.PubMedCrossRef
122.
Geffers I, Serth K, Chapman G, et al. Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo. J Cell Biol. 2007;178(3):465–76.PubMedPubMedCentralCrossRef
123.
Tanaka K, Isse K, Fujihira T, et al. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116–20.PubMedCrossRef
124.
Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clin Cancer Res. 2021;27(5):1526–37.PubMedCrossRef
125.
Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol: off J Am Soc Clin Oncol. 2023;41(16):2893–903.CrossRef
126.
Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023;389(22):2063–75.PubMedCrossRef
Metadata
Title
Small Cell Lung Cancer—An Update on Chemotherapy Resistance
Authors
Qian Ying
Ruiyun Fan
Yili Shen
Boyi Chen
Jianhui Zhang
Qiuhui Li
Xuefei Shi
Publication date
27-07-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 8/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-024-01245-w

Other articles of this Issue 8/2024

Current Treatment Options in Oncology 8/2024 Go to the issue

ReviewPaper

Opportunities and Challenges in Soft Tissue Sarcoma Risk Stratification in the Era of Personalised Medicine

ReviewPaper

Progress in immunotherapy for biliary tract cancer

ReviewPaper

Evolution of Treatment Strategies for Gestational Trophoblastic Neoplasia: Chemotherapy, Immunotherapy, and Molecular Targeted Therapy

ReviewPaper

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

ReviewPaper

Treatment options for brain metastases

ReviewPaper

Advancements in Melanoma Therapies: From Surgery to Immunotherapy
Image Credits